BridgeMD
Compares treatment options for Extensive-Stage Small Cell Lung Cancer
Official title A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
ClinicalTrials.gov ID: NCT06646276
What this study is testing
What is BMS-986489 (BMS-986012+Nivolumab)?
BMS-986489 (BMS-986012+Nivolumab) is an investigational medicine, being studied as a potential treatment for extensive-stage small cell lung cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
- Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain...
You likely can't join if
- Participants have already received certain types of treatment for extensive stage small cell lung cancer
- Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases...
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Daphne, Alabama, United States
- Hot Springs, Arkansas, United States
- Fort Myers, Florida, United States
- Orange City, Florida, United States
- St. Petersburg, Florida, United States
- Marietta, Georgia, United States
- Peoria, Illinois, United States
- Minneapolis, Minnesota, United States
- Albuquerque, New Mexico, United States
- Durham, North Carolina, United States
- Bismarck, North Dakota, United States
- Fargo, North Dakota, United States
- Cincinnati, Ohio, United States
- Sioux Falls, South Dakota, United States
- Nashville, Tennessee, United States
- Austin, Texas, United States
- Tyler, Texas, United States
- Roanoke, Virginia, United States
- Edmonds, Washington, United States
- Seattle, Washington, United States
+ 145 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Daphne, Alabama, United States; Hot Springs, Arkansas, United States; Fort Myers, Florida, United States; Orange City, Florida, United States; St. Petersburg, Florida, United States; Marietta, Georgia, United States and 159 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.